Outcomes in COVID-19 tenecteplase studies

0 0.5 1 1.5+ All studies -25% 1 13 Improvement, Studies, Patients Relative Risk Mortality -25% 1 13 Hospitalization 15% 1 13 RCTs -25% 1 13 Late -25% 1 13 Tenecteplase for COVID-19 c19early.org November 2025 Favorstenecteplase Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Poor (DB RCT) -25% 1.25 [0.15-10.5] death 2/8 1/5 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.85 Late treatment -25% 1.25 [0.15-10.5] 2/8 1/5 25% higher risk All studies -25% 1.25 [0.15-10.5] 2/8 1/5 25% higher risk 1 tenecteplase COVID-19 study c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.85 Effect extraction pre-specified(most serious outcome) Favors tenecteplase Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Poor (DB RCT) -25% 1.25 [0.15-10.5] 2/8 1/5 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.85 Late treatment -25% 1.25 [0.15-10.5] 2/8 1/5 25% higher risk All studies -25% 1.25 [0.15-10.5] 2/8 1/5 25% higher risk 1 tenecteplase COVID-19 mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.85 Favors tenecteplase Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Poor (DB RCT) 15% 0.85 [0.23-3.15] hosp. time 8 (n) 5 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.82 Late treatment 15% 0.85 [0.23-3.15] 8 (n) 5 (n) 15% lower risk All studies 15% 0.85 [0.23-3.15] 8 (n) 5 (n) 15% lower risk 1 tenecteplase COVID-19 hospitalization result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.82 Favors tenecteplase Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Poor (DB RCT) -25% 1.25 [0.15-10.5] death 2/8 1/5 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.85 Late treatment -25% 1.25 [0.15-10.5] 2/8 1/5 25% higher risk All studies -25% 1.25 [0.15-10.5] 2/8 1/5 25% higher risk 1 tenecteplase COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.85 Effect extraction pre-specified(most serious outcome) Favors tenecteplase Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Poor (DB RCT) -25% 1.25 [0.15-10.5] 2/8 1/5 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.85 Late treatment -25% 1.25 [0.15-10.5] 2/8 1/5 25% higher risk All studies -25% 1.25 [0.15-10.5] 2/8 1/5 25% higher risk 1 tenecteplase COVID-19 RCT mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.85 Favors tenecteplase Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Poor (DB RCT) -25% 1.25 [0.15-10.5] death 2/8 1/5 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.85 Late treatment -25% 1.25 [0.15-10.5] 2/8 1/5 25% higher risk All studies -25% 1.25 [0.15-10.5] 2/8 1/5 25% higher risk 1 tenecteplase COVID-19 peer reviewed studies c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.85 Effect extraction pre-specified(most serious outcome) Favors tenecteplase Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Poor (DB RCT) -25% 1.25 [0.15-10.5] death 2/8 1/5 Improvement, RR [CI] Treatment Control Poor (DB RCT) -25% 1.25 [0.15-10.5] death 2/8 1/5 Poor (DB RCT) 38% 0.62 [0.20-1.97] progression 3/8 3/5 Poor (DB RCT) 15% 0.85 [0.23-3.15] hosp. time 8 (n) 5 (n) Tenecteplase COVID-19 outcomes c19early.org November 2025 Favors tenecteplase Favors control